Kaoru Fujinami
UCL Institute of Ophthalmology
142 Papers
283 Citations
Kaoru Fujinami is an academic researcher from UCL Institute of Ophthalmology. The author has contributed to research in topics: Medicine & Visual acuity. The author has an hindex of 23, co-authored 105 publications. Previous affiliations of Kaoru Fujinami include Moorfields Eye Hospital & University of Tokyo.
Chat about Author
Papers
Internal Limiting Membrane Peeling to Prevent Post-vitrectomy Epiretinal Membrane Development in Retinal Detachment.
TL;DR: ILM peeling without ICG staining during the initial vitrectomy for RRDs may prevent postoperative ERM formation with favorable visual outcomes, and there was no significant difference in the final BCVA between subgroups with and without ILMpeeling.
72
Early Patterns of Macular Degeneration in ABCA4-Associated Retinopathy
Kamron N. Khan,Kamron N. Khan,Kamron N. Khan,Melissa Kasilian,Omar A. Mahroo,Omar A. Mahroo,Preena Tanna,Preena Tanna,Angelos Kalitzeos,Angelos Kalitzeos,Anthony G. Robson,Anthony G. Robson,Kazushige Tsunoda,Takeshi Iwata,Anthony T. Moore,Anthony T. Moore,Anthony T. Moore,Kaoru Fujinami,Michel Michaelides,Michel Michaelides +19 more
TL;DR: In childhood-onset ABCA4-associated retinopathy, the earliest stages of macular atrophy involve the parafovea and spare the foveola and in some cases, these changes are predated by tiny, foveal, yellow, hyperautofluorescent dots.
71
Visual Acuity Loss and Associated Risk Factors in the Retrospective Progression of Stargardt Disease Study (ProgStar Report No. 2).
Xiangrong Kong,Rupert W. Strauss,Rupert W. Strauss,Rupert W. Strauss,Michel Michaelides,Artur V. Cideciyan,José-Alain Sahel,Beatriz Munoz,Sheila K. West,Hendrik P. N. Scholl,Yulia Wolfson,Millena Bittencourt,Syed Mahmood Shah,Mohammed Ahmed,Etienne M Schönbach,Kaoru Fujinami,Elias I. Traboulsi,Justis P. Ehlers,Meghan J Marino,Susan Crowe,Rachael Briggs,Angela Borer,Anne Pinter,Tami Fecko,Nikki Brugnoni,Janet S. Sunness,Carol A. Applegate,Leslie Russell,Anthony T. Moore,Andrew R. Webster,Sophie Connor,Victoria McCudden,Maria Pefkianaki,Jonathan Aboshiha,Gerald Liew,Graham E. Holder,Anthony G. Robson,Alexa King,Daniela Ivanova Cajas Narvaez,Katy Barnard,Catherine Grigg,Hannah Dunbar,Yetunde Obadeyi,Karine Girard-Claudon,Hilary Swann,Avani Rughani,Charles Amoah,Dominic Carrington,Kanom Bibi,Emerson Ting Co,Andrew Carter,Anne Georgiou,Selma Lewis,Saddaf Shaheen,Harpreet Shinmar,Linda Burton,Paul S. Bernstein,Kimberley Wegner,Briana Lauren Sawyer,Bonnie Carlstrom,Kellian Farnsworth,Cyrie Fry,Melissa Chandler,Glen Jenkins,Donnel Creel,David G. Birch,Yi-Zhong Wang,Luis Rodriguez,Kirsten G. Locke,Martin Klein,Paulina Mejia,Samuel G. Jacobson,Sharon B. Schwartz,Rodrigo Matsui,Michaela L. Gruzensky,Alejandro J. Roman,Eberhart Zrenner,Fadi Nasser,Gesa Astrid Hahn,Barbara Wilhelm,Tobias Peters,Benjamin Beier,Tilman Koenig,Susanne Kramer,Saddek Mohand-Said,Isabelle Audo,Caroline Laurent-Coriat,Ieva Sliesoraityte,Christina Zeitz,Fiona Boyard,Minh Ha Tran,Mathias Chapon,Céline Chaumette,Juliette Amaudruz,Victoria Ganem,Serge Sancho,Aurore Girmens,Robert Wojciechowski,Shazia Khan,David Emmert,Dennis Cain,Mark Herring,Jennifer Bassinger,Lisa Liberto,Ann-Margret Ervin,Kurt Dreger,Jennifer Jones,Srinivas R. Sadda,Anamika Jha,Alex Ho,Brendan Kramer,Amirhossein Hariri,Gloria Blanquel,Ngoc Lam,Sean Pitetta,Yue Shi,Rita Tawdros,Christine Petrossian,Dennis Jenkins,Muneeswar Gupta,Yong Dong Zhou,Katherine Aguilar,Cynthia Chan,Lisa Santos,Brian Seo,Christopher Sison,Silvia Perez,Stephanie Chao,Kelly Miyasato,Julia Higgins,Zoila Luna,Anita Menchaca,Norma Gonzalez,Vicky Robledo,Karen Carig,Kirstie Baker,David Ellenbogen,James Russell,Daniel Bluemel,Alex Moreno,Royal Pham,Theo Sanford,Daisy Linares,Mei Tran +143 more
TL;DR: Given the overall slow rate of VA loss, VA is unlikely to be a sensitive outcome measure for treatment trials of Stargardt disease, however, given the faster decline in younger patients and those with no or mild visual impairment, VA may be a potential outcomeMeasure for trials targeting such subgroups of patients.
65
Inherited cataracts: molecular genetics, clinical features, disease mechanisms and novel therapeutic approaches
Vanita Berry,Vanita Berry,Michalis Georgiou,Michalis Georgiou,Michalis Georgiou,Kaoru Fujinami,Kaoru Fujinami,Roy A. Quinlan,Anthony T. Moore,Anthony T. Moore,Michel Michaelides,Michel Michaelides,Michel Michaelides +12 more
TL;DR: The variable cataract phenotypes and molecular mechanisms, including genotype–phenotype correlations, are detailed, and future novel therapeutic avenues including cellular therapies and pharmacological treatments are explored.
64
Novel RP1L1 Variants and Genotype-Photoreceptor Microstructural Phenotype Associations in Cohort of Japanese Patients With Occult Macular Dystrophy.
Kaoru Fujinami,Shuhei Kameya,Sachiko Kikuchi,Shinji Ueno,Mineo Kondo,Takaaki Hayashi,Kei Shinoda,Shigeki Machida,Kazuki Kuniyoshi,Yuichi Kawamura,Masakazu Akahori,Kazutoshi Yoshitake,Satoshi Katagiri,Ayami Nakanishi,Hiroyuki Sakuramoto,Yoko Ozawa,Kazuo Tsubota,Kunihiko Yamaki,Atsushi Mizota,Hiroko Terasaki,Yozo Miyake,Takeshi Iwata,Kazushige Tsunoda +22 more
TL;DR: The significant association of the morphologic phenotypes and genotypes indicates that there are two types of pathophysiology underlying the occult macular dysfunction syndrome: a hereditary OMD with the classical phenotype (Miyake's disease), and a nonhereditary OMD-like syndrome with progressive occult maculopathy.
63